Ethical considerations in implementation research: a scoping review of key principles, unintended consequences, and emerging ethical guidance Authors: Emmanuel K Tetteh, Nwaliweaku Anidi, Gifty Aboagye-Mensah, Michelle Doering, Elvin H Geng, Byron J Powell, Mark D Huffman, Alison L Antes Published: 2025 ABSTRACT AbstractBackgroundAs dissemination and implementation research advances, research teams seek guidance on how to apply existing ethical standards to implementation research, given its unique study designs, multi-level intervention targets, and associated risks. This scoping review examines ethical principles and concerns in implementation research, identifies potential risks and unintended consequences, and explores ethical frameworks guiding responsible conduct.MethodsWe searched PubMed, Web of Science, and Google Scholar for relevant literature published between January 2010 and January 2024. The search utilized a combination of standardized terms and keywords, including bioethics, ethics, research standards, responsible research, health services research, and dissemination and implementation science. Two reviewers independently extracted data on study characteristics, ethical considerations, and recommendations. We applied thematic analysis using deductive coding to identify key ethical domains and unintended consequences.ResultsThe search returned 1,003 articles, of which 791 unique citations underwent screening. We included 44 articles that discussed ethical principles, risks, unintended consequences, or ethical frameworks in implementation research. The most identified ethical challenges were complexities in informed consent for system or multilevel interventions (55% of articles), equipoise regarding established interventions in new contexts (36%), inconsistencies in regulatory oversight (34%), and the need for robust risk–benefit assessments (32%). Frequently discussed unintended consequences included burnout of health providers (25%), failure to sustain interventions (25%), reduced participant autonomy (23%), stigma (20%), and equity concerns (20%). Three key findings emerged. First, while general ethical principles apply, researchers and review boards struggle with their implementation, particularly in informed consent, equipoise, and risk–benefit assessment. Second, implementation research primarily presents socio-behavioral risks, such as stigma, loss of trust, equity concerns, and burnout, rather than clinical adverse events. Third, existing ethical frameworks remain fragmented, with no consensus standards for oversight.ConclusionsEthical challenges in implementation research require clearer oversight and better-adapted frameworks. Existing guidance remains fragmented, leading to inconsistent risk assessments. Addressing socio-behavioral risks and unintended consequences is crucial. Strengthening ethical oversight will require consensus-driven standards, training, and further empirical research on the unique risks posed by implementation research.Trial registrationThe protocol for this manuscript was registered prospectively and published on the Open Science Framework (https://doi.org/10.17605/OSF.IO/7XFWY).Supplementary InformationThe online version contains supplementary material available at 10.1186/s43058-025-00845-3.Keywords: Ethical considerations, Dissemination and implementation research, Research ethics, Unintended consequences, Pragmatic trials, Implementation science This scoping review identifies key ethical challenges specific to dissemination and implementation research, including informed consent complexities, equipoise in implementation trials, and gaps in regulatory oversight. This scoping review identifies key ethical challenges specific to dissemination and implementation research, including informed consent complexities, equipoise in implementation trials, and gaps in regulatory oversight. The multilevel nature of implementation research creates unique ethical considerations. Additionally, unintended consequences, such as provider burnout, stigma, and failure to sustain interventions, more common in implementation research are often overlooked or not in existing ethical frameworks. The multilevel nature of implementation research creates unique ethical considerations. Additionally, unintended consequences, such as provider burnout, stigma, and failure to sustain interventions, more common in implementation research are often overlooked or not in existing ethical frameworks. This study found that while multiple ethical frameworks exist, they remain fragmented and lack tailored guidance. This study found that while multiple ethical frameworks exist, they remain fragmented and lack tailored guidance. A clearer definition of what risks are considered "minimal" within the context of implementation science is important to guide ethical decision-making and oversight. A clearer definition of what risks are considered "minimal" within the context of implementation science is important to guide ethical decision-making and oversight. Background Implementation research raises a range of ethical challenges that are either absent or less pronounced in conventional biomedical research paradigms. For instance, interventions may target institutions rather than individuals, creating blurred lines around informed consent and participant autonomy [1]. Research subjects may include health professionals, managers, or entire communities, complicating assessments of risk and benefit. Implementation research often involves adaptive interventions or partial rollout strategies that raise questions about fairness, equipoise, and sustainability, particularly in resource-constrained settings [1]. Foundational ethical principles such as autonomy, beneficence, non-maleficence, and justice remain relevant, but their application becomes more complex in the implementation context. Emerging trial designs and embedded methodologies challenge the assumptions that underpin traditional research ethics oversight [2, 3]. At the same time, ethics review committees and governance bodies may lack clear guidance on how to evaluate the ethical integrity of implementation studies [4, 5]. While implementation research does not necessitate new ethical principles, it does require careful attention to context [6]. However, defining and applying context within implementation research is often complex and poses additional challenges for institutional review boards, many of which lack extensive experience with implementation research and lack adapted ethical frameworks to guide their evaluations. As a result, ethical and regulatory bodies face increasing pressure to refine their approaches to ethical oversight in a field that does not always align neatly with traditional biomedical research ethics [5, 7]. In response to these challenges, research teams have called for the development of consensus standards [6, 8], while others have proposed a structured roadmap to achieve such standards [4]. To ensure that any developed consensus framework is both comprehensive and applicable in supporting researchers, ethical review boards, and policymakers in the responsible conduct of implementation research, there are several key questions that must first be addressed. These questions include: What ethical principles and considerations are most relevant to the responsible conduct of implementation research? What potential risks and unintended consequences may be unique to this field? and Which existing ethical frameworks or standards currently guide implementation research? Therefore, the objective of this scoping review is to systematically explore the breadth, consistency, and availability of published literature on ethical concerns, associated risks, and available guidance for the responsible conduct of implementation research. By scoping and synthesizing the current body of knowledge, this work seeks to establish a foundation for ethical decision-making in implementation research, ensuring that ethical principles are effectively contextualized while mitigating potential risks and unintended consequences. Furthermore, a thorough understanding of these ethical considerations will help inform the development of future guidelines and frameworks to support the responsible conduct of implementation research. Methods Protocol and registration The review was guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews (PRISMA-ScR) [9] (see Additional File 1) and the Joanna Briggs Institute (JBI) Manual for Evidence Synthesis [10]. The study protocol is available on Open Science Framework [11]. Scoping review questions The overarching study question was: “What ethical questions and frameworks exist in the conduct of implementation research?”. The specific sub-questions were: (1) What are ethical principles and questions raised in implementation research? (2) What are the risks and unintended consequences of conducting implementation research? (3) What ethical frameworks or standards are available to guide the responsible conduct of implementation research? Search strategy The published literature was searched using strategies created by a medical librarian (MD). The search was conducted on January 29, 2024, in PubMed, Embase.com, Scopus, and Web of Science. The search string comprised of keywords including, but not limited to, (bioethics OR ethics OR ethical) AND (research standards OR study design OR responsible research OR clinical trials as topic OR health services research) AND (implementation). A date limit of 2010 – current was applied. We initially considered 2006, which is the year Implementation Science Journal published its first issue, but this yielded an overwhelming number of results, often not related to implementation or health systems research. Hence, we selected 2010 as a pragmatic cutoff to balance comprehensiveness with feasibility, while still capturing over a decade of relevant literature reflecting the evolution of implementation science. The language was limited to English. There was a total of 1,003 results. Two hundred and eight (208) duplicates were assumed to be accurately identified in Covidence, bringing the final total to 791 unique citations. Full search strategies are provided in Additional File 2. Inclusion and exclusion criteria English publications and full-text English translations that were publicly accessible and available through the Bernard Becker Academic Library were eligible for inclusion. We included all study settings, age groups, genders, and populations related to the responsible conduct of research in implementation research. Theoretical and original studies, frameworks, commentaries (including editorials), and methodology articles were the types of publications included in this review. All types of articles, including books, reports, clinical trials, meta-analyses, randomized controlled trials, grey literature, reviews, and systematic reviews, were also considered. Blogs and website articles that are not peer-reviewed, as well as bioethical discussions unrelated to health services research, including implementation research, were excluded. Data screening Screening was conducted in two stages using Covidence, based on our predefined eligibility criteria discussed above. In the first stage, three reviewers (ET, GAM, and NA) independently assessed the relevance of each title and abstract, with each record being reviewed by two separate reviewers. Citations receiving two "yes" votes were deemed relevant and progressed to the full-text screening stage. Disagreements were resolved through consensus, or if needed, by consulting an additional member of the research team. Full texts of the selected citations were obtained and uploaded for further review. In the second stage, the same three reviewers screened the full-text articles, with two reviewers independently assessing each article. Articles that received two "yes" votes were advanced to the data extraction phase (see Fig. 1 for the PRISMA-ScR diagram). PRISMA Flow Diagram Data extraction and charting Two independent reviewers extracted and charted the data using a data extraction form aligned with the research aims and objectives (see Additional File 3). Discrepancies (~ 12% of the time) were resolved through discussion and consensus during weekly meetings. The data extraction form was piloted using five studies. Additionally, two independent reviewers assessed the full-text of selected citations against the inclusion criteria. Reasons for the exclusion of full-text studies not meeting the criteria are documented and reported in Fig. 1. The following data points were collected: (1) general study information which included first author’s last name, article title, publication year, country of the first author's primary institution, study aim, and article type (e.g., commentary, debate, original research, or review). (2) Ethical principles and considerations relevant to implementation research. (3) Details on specific study designs or participant populations pertinent to the responsible conduct of implementation research. (4) Negative unintended consequences identified in the context of implementation research. (5) Ethical frameworks and guidelines that were discussed, developed, or used to guide implementation research. (6) Suggestions or recommendations proposed by the authors. Data analysis and synthesis The characteristics of the included studies and data were organized and tabulated using information from the standardized data extraction forms. Descriptive statistics were applied to summarize the key attributes of the included studies, using SPSS Statistical Software [12]. We conducted a thematic analysis using a deductive coding framework to identify ethical principles, issues, and unintended consequences discussed in the implementation research literature. Our analysis proceeded through the following structured steps: Codebook development We developed a codebook based on a deductive approach, informed by team members expertise, including a bioethicist (ALA) and implementation science experts (EKT, BJP, EHG, MDH), as well as insights from prior literature reviews. The initial set of codes included domains such as autonomy, informed consent, regulatory oversight, risk–benefit ratio, stigma, burnout, equipoise, and scientific validity. The codebook was pilot-tested using five articles and iteratively refined to improve clarity and coding consistency. Unit of analysis The individual article served as the primary unit of analysis. However, codes were applied to specific paragraphs or thematic sections within each article to capture the full range of ethical discussions. This allowed for multiple codes to be assigned to a single article where applicable. Coding process Two reviewers independently applied the codes using structured extraction forms. Ethical issues were coded when they were explicitly described or implicitly referenced in the text. Discrepancies in coding were resolved through discussion in weekly consensus meetings to ensure interpretive alignment. Synthesis of findings Once all articles were coded, we summarized the presence and distribution of each code across the dataset. No higher-order themes were imposed. Instead, the findings are reported at the code level to preserve specificity. Frequencies are presented in tabular form (see Table 1), with descriptive interpretation provided in the Results section. Table 1Summary of characteristics of included articles (N = 44)Characteristicsn (%)Reference(s)WHO Region African Region3 (6.8)[5, 13, 14] European Region11 (25.0)[15–24] Region of the Americas24 (54.5)[1, 4, 25–46] South-East Asian Region2 (4.5)[2, 47, 48] Western Pacific Region4 (9.1)[49–52]Article Type Commentary21 (47.7)[2, 4, 13, 15, 16, 20, 23, 25–28, 30, 31, 33, 34, 40, 43, 44, 47–49] Debate2 (4.9)[42, 50] Original Research13 (29.5)[1, 5, 14, 19, 22, 35–39, 41, 51, 52] Report1 (2.3)[21] Review7 (15.9)[17, 18, 24, 29, 32, 45, 46]Specific Populations of Interest Children and Minors5 (11.1)[1, 27, 35, 42, 52] Elders2 (4.4)[24, 43] Ethnic Minorities3 (6.7)[19, 37, 40] Low- and Middle-Income Countries (LMICs)10 (22.2)[2, 14, 15, 17, 21, 25, 27–29, 49] Not Specific25 (55.6)Study Designs and Research Methods of Interest* Cluster Randomized Trials13 (29.5)[1, 2, 4, 5, 21, 23, 26, 28, 29, 37, 38, 47, 51] Co-design and Participatory Action Research9 (20.5)[1, 22, 37, 39, 40, 42, 45, 47, 50] Electronic and Information Technology Methods4 (9.1)[5, 14, 24, 46] Hybrid Trials3 (6.8)[17, 47, 51] Pragmatic Trials7 (15.9)[2, 14, 30, 31, 36, 38, 47] Stepped Wedge Designs8 (18.2)[1, 2, 4, 5, 21, 23, 28, 47] Qualitative Research2 (4.5)[47, 51] Not specific19 (43.2)Topics of Ethical Concern* Autonomy12 (27.3)[13, 14, 16, 24, 31, 35, 37–39, 43, 45, 50] Confidentiality7 (15.9)[16, 31, 40–43, 47] Equipoise16 (36.4)[1, 2, 4, 5, 15–18, 23, 26, 28, 33, 36, 38, 47, 51] Equity8 (18.2)[13, 16, 35, 39, 41–43, 49] Informed Consent24 (54.5)[1, 2, 4, 5, 13, 14, 16, 18–20, 26, 28–31, 33, 36, 38, 42–44, 46, 47, 51] Minimal Risk8 (18.2)[4, 26, 27, 29, 30, 34, 39, 40] Participatory and Community Engagement10 (22.7)[2, 13, 16, 21, 31–33, 40, 41, 47] Scientific Validity9 (20.5)[1, 5, 13–15, 21, 22, 29, 38] Risk–Benefit Ratio14 (31.8)[2, 5, 13, 16, 20, 21, 25, 28, 31, 33, 34, 37, 38, 51] Regulatory Oversight15 (34.1)[2, 4, 5, 13, 14, 18, 21, 23, 25, 38, 44, 46, 48, 51, 52]Unintended Consequences* Burnout and Increased Workload11 (25.0)[4, 14, 19, 28, 33–36, 40, 45, 52] Denial of standard of care7 (15.9)[17, 20, 26, 28, 32, 38, 47] Equity Concerns9 (20.5)[20, 27, 28, 35, 37, 39, 40, 43, 47] Lack of Sustainability11 (25.0)[4, 21, 22, 24, 28, 29, 34, 35, 37, 39, 47] Loss of Autonomy10 (22.7)[19, 28, 29, 32, 33, 35, 36, 38, 39, 47] Loss of Trust8 (18.2)[14, 19, 20, 31, 35, 40, 41, 47] Stigma9 (20.5)[17, 19, 27, 29, 35, 37, 41, 43, 47] No Unintended Consequence Reported17 (38.6)*Categories were not mutually exclusive (some articles included more than one) Summary of characteristics of included articles (N = 44) *Categories were not mutually exclusive (some articles included more than one) Ensuring rigor and transparency To ensure methodological transparency, we maintained a detailed audit trail of coding decisions, team discussions, and interpretive notes. Additional File 4 provides exemplar excerpts showing how selected codes were applied and interpreted within the source articles. Results Searches yielded 1,003 records from electronic databases. After removing duplicates, 791 unique publication titles and abstracts were screened for inclusion, of which 150 proceeded to full-text screening. Screening the reference lists of included articles and consulting with experts identified an additional 4 citations to include in full-text screening. Ultimately, 44 articles were included in the review (see Fig. 1). The most common reason for excluding articles during full-text screening was that they did not discuss ethics specific to implementation research. Study characteristics A detailed bibliography and qualitative summaries of the included articles are provided in Additional File 5. See Table 1 for descriptive characteristics. Most articles’ first authors were affiliated with institutions in the Americas (n = 24, 54.5%), with 18 (40.9%) out of all articles originating from the United States alone. Eleven articles (25.0%) were from the European Region, while fewer articles originated from Western Pacific Region (n = 4, 9.1%), the African Region (n = 3, 6.8%), and the South-East Asian Region (n = 2, 4.5%); see Fig. 2. Nearly half of included articles were commentaries (n = 21, 47.7%), followed by original studies (n = 13, 29.5%). Specific populations were addressed in a subset of the studies, including children and minors (n = 5, 11.1%), elders (n = 2, 4.4%), and ethnic minorities (n = 3, 6.7%). Ten articles (22.2%) focused on low- and middle-income countries (LMICs), while the majority (n = 25, 55.6%) did not target any specific population. Distribution of publications by primary author affiliation across WHO regions The articles discussed a variety of study designs and research methods used in implementation research. Thirteen articles (20.0%) focused on cluster randomized trials, 9 (13.8%) on co-design and participatory action research, and 7 (10.8%) on pragmatic trials. Other methods discussed included stepped wedge designs (n = 8, 12.3%), electronic and information technology methods (n = 4, 6.2%), and hybrid effectiveness-implementation studies (n = 3, 4.6%). Ethical issues in qualitative research methodologies were addressed in two articles (3.1%), while 19 articles (29.2%) did not specify a particular study design or research method in their ethical discussions. Publication trend analysis Figure 3 presents a scatter plot illustrating publication frequencies by year. The positive upward trajectory in publication frequency from 2010 to 2023 suggests that ethics is becoming an increasingly important topic within implementation research and reflects the overall growth of the implementation research field more broadly. Although there are fluctuations in publication frequency from year to year, certain peaks stand out, particularly in 2014, as well as in 2019 and 2020. Notably, the 2014 publications predominantly focused on the needs of health systems research ethics, including translational and implementation research within the global health context, with an emphasis on LMICs. Key issues explored during this period included the use of big data [15], distinctions between practice (treatment) and research [25, 26], equity and intercultural considerations [27, 49], and research oversight [25, 28, 29]. Scatter plot of publication frequencies by year In 2016, Wassenaar and colleagues notably proposed an adaptation of the Emanuel framework for clinical research ethics to address the unique challenges faced by LMIC health systems research [13], challenges that had been highlighted by earlier authors. In the following years, Luyckx and colleagues reported on the World Health Organization's efforts regarding the ethics of implementation science, including the development of toolkits and Massive Open Online Courses (MOOCs) [16]. A collection of papers dedicated to The Ethics of Alternative Clinical Trial Designs and Methods in LMIC Research was published in the Trials journal in 2019 [53], addressing contemporary ethical considerations in study designs that are increasing in popularity in implementation research such as adaptive designs, cluster randomized trials, and stepped-wedge designs,. In 2019 and later years, additional guidance and recommendations emerged in other areas relevant to implementation research such as pragmatic trials [30, 31], de-implementation [32], equipoise [17], and global health research oversight [18, 33]. More recent publications have explored the unintended consequences of implementation research [19, 34, 35], and the ethical dimensions of pragmatic trials [14, 30, 31, 36], reflecting the ongoing evolution of the field and its increasing complexity. Tables 2 and 3 summarize findings of ethical considerations and unintended consequences. Table 2Summary of results on ethical principles and key Considerations in Implementation Science ResearchEthical PrinciplesDefinitionsRaised concerns in Implementation researchConsiderations for the responsible conduct of implementation researchAutonomyThe right and capacity of individuals to make informed, independent decisions, shaped by both personal choices and social relationships, while being respected and empowered within the research processLack of appropriate informed consent, transparency, and the potential use of deception especially in low-resource settingsBalancing individual informed decision-making with collaborative, participatory engagement, and ensuring that participants are both empowered and safeguardedConfidentialityThe obligation to protect participants' private information and ensure anonymity where appropriateChallenges in de-identifying data, particularly in small, interconnected communities and research designs like pragmatic trialsUsing proactive and participatory approaches, as well as pseudonyms and anonymization to maintain confidentialityThe risks of unintentional breachesBalancing privacy with the right to informationEquipoiseEthical principle requiring genuine uncertainty about the best intervention to ensure fairness in researchEquipoise in implementation research extends far beyond the intervention to include situational and contextual uncertaintiesConsider both the intervention’s proven effectiveness and its practical application across diverse settingsImplications of delaying evidence-based interventions for control groupsEthical justification for study designs to ensure that justice and fairness are metEquityThe fair distribution of research benefits and burdens, addressing systemic inequities and power imbalancesExclusion of marginalized voices, disparities in access, the influence of socio-economic and colonial legacies, as well as risks of coercionCentering community engagement to ensure inclusive and equitable research processesInformed ConsentThe process by which participants are given comprehensive, understandable information to voluntarily decide on their participationConsent ambiguities in group-level interventions, cluster randomized trials, and vulnerable populations; therapeutic misconceptionsAdapting consent mechanisms to be an ongoing, accessible supportive process that reflects cultural, linguistic, and power dynamicsMinimal RiskThe principle that research should not expose participants to risks greater than those encountered in daily lifeDifficulty in assessing less immediate and harder-to-measure risks associated with Implementation researchNeed for a systematic framework to assess risks in pragmatic trials making sure to consider distributive justice principles, distinguish between research and non-research public health activities, its associated respective risks and highlight need for ethical oversightParticipatory and Community EngagementThe active involvement of community members in shaping, conducting, and benefiting from researchRisks of tokenism, failure to address systemic inequities, and ethical dilemmas in balancing transparency with confidentialityEstablishing advisory boards, fostering ethical reflexivity, and tailoring engagement strategies to ensure respect, trust, and cultural sensitivityScientific ValidityEnsuring research methods/designs are appropriately designed to answer research questions while being ethically and contextually soundRisks of using inappropriate designsSelecting scientifically valid and contextually appropriate designs, and maintaining transparency on limitations of study designsChallenges with big data ethicsAddressing uncertainties and unforeseen variables- i.e. impactful events that cannot be predicted or prevented beforehand- through ethical reviewsRisk–Benefit RatioWeighing potential risks against anticipated benefits for participants and communitiesDifficulty in predicting harms, risks extending beyond individuals to communities, ethical challenges in stepped-wedge trials and intervention rolloutsDeveloping clear ethical guidelines to navigate these concerns, ensuring that research benefits outweigh risksRegulatory OversightThe systems and frameworks ensuring ethical compliance in researchDistinguishing implementation research from program evaluation and quality improvement, inconsistent ethical review processes, and inadequate regulatory frameworksEnhancing ethics review committee expertise, developing tailored ethical guidelines, and integrating flexible oversight mechanisms Summary of results on ethical principles and key Considerations in Implementation Science Research Table 3Unintended consequences arising in implementation researchUnintended consequencesApplication in implementation researchConsiderations for the responsible conduct of implementation researchBurnout and Increased WorkloadAdditional strain on healthcare staff, especially in overwhelmed systems; and poorly designed training programs leading to dissatisfaction and turnoverA call for better planning, resource allocation, and study design to minimize burdens and ensure ethical and sustainable research practicesEquity ConcernsNeglect of critical healthcare services and widening of health disparities due to resource limitations; delayed access in phased rollouts; and exclusion of marginalized populationsRequires stakeholder engagement, adaptive study designs, and inclusive post-approval research to address these concernsDenial of Standard of CareControl groups not receiving effective interventions, difficulty defining standard care in resource-limited settings, exclusionary research criteria limiting access to benefits, and de-implementing low-value care without careful planningResearchers must ensure ethical standards by providing at least usual care, addressing local disparities, and minimizing delays in effective treatment accessLack of SustainabilityReliance on short-term funding, ethical concerns over financial incentives affecting participation, system changes (e.g., staff turnover, policy shifts) undermining long-term program fidelityProactively plan for long-term sustainability through policy integration, community involvement, and diversified funding sources to maintain program impact beyond the study phaseLoss of AutonomyResearch designs (e.g., performance measurement, cluster randomized trials) limiting patient-centered decision-making, coercive effects of financial incentives, and technology reducing personal control (e.g., in elder care)Ensure transparent decision-making, provide ethical guidance on incentive structures, and design interventions that enhance both individual and collective autonomyLoss of TrustMistrust due to financial incentives being misinterpreted, confidentiality concerns (e.g., use of recordings), lack of sustainability planning, financial conflicts of interest, cultural insensitivity, and poor communicationFoster transparency in research objectives and incentive structures, ensure cultural alignment, maintain confidentiality protections, and engage communities in research design to sustain trust beyond the study periodStigmaHealth interventions inadvertently stigmatizing vulnerable groups (e.g., mental health patients, MSM, women in LMICs), with risks heightened by cultural and social contextsConduct safeguarding strategies, like situational analyses, before implementation to balance potential benefits and stigma risks Unintended consequences arising in implementation research Ethical principles and key considerations in implementation research Autonomy Central to the discussion on respecting participants’ autonomy in implementation research is the balance between informed consent and transparency, with concerns that withholding information, such as details about study arms, may undermine autonomy, especially in vulnerable populations [37, 38]. Authors highlight the concept of autonomy as it relates to independence and self-determination in decision-making. In the context of an implementation trial that tests decision support strategies or tracks health provider practices, providers involved in the trial may feel their autonomy is reduced, such as through excessive monitoring, control, or micromanagement, which can lead to a loss of agency, dissatisfaction, or disengagement [35]. Co-creation and participatory research approaches, where participants are not just subjects but active partners in shaping the research, have been suggested as ways of increasing agency and involvement [39, 50]. This evolving understanding of autonomy incorporates both individual and relational aspects, recognizing that decisions are shaped by social contexts and responsibilities [16, 41]. Community engagement Community engagement is discussed as a fundamental ethical principle across diverse contexts, underscoring the importance of respect, trust, and cultural sensitivity. Strategies such as forming advisory boards, conducting consultative processes, and adopting culturally sensitive practices are recommended to foster informed consent, amplify marginalized voices, and tackle systemic inequities [2, 13, 31, 33, 40]. Authors emphasize that transparency in sharing results must balance confidentiality with the community's right to information [32, 41]. For instance, engaging local knowledge brokers and tailoring dissemination strategies to community preferences ensure that findings are communicated responsibly and respectfully. This process also facilitates trust and sustainability in research, particularly in contexts where low-value treatments are de-implemented or where public acceptance of novel methods is critical [21, 32]. Across these discussions, ethical reflexivity, capacity building, and inclusive dialogue are emphasized as essential to integrating community engagement into research practices, ultimately enhancing the ethical integrity and social justice of implementation, and dissemination efforts [33, 40, 47]. Confidentiality Implementation strategies, such as using treatment partners, peer support, and other community-based strategies, make maintaining confidentiality in implementation research complex [40]. Authors note the challenges of maintaining confidentiality in small, interconnected communities in low-income countries, where blinding study arms, and the dissemination of results may inadvertently breach privacy [41, 47]. Several authors argue that approaches to addressing confidentiality should be both proactive and participatory [16, 41–43, 47]. For instance, Baumann and colleagues demonstrates how explaining data handling and rights to underserved populations can alleviate fears and foster participation [40]. However, proactive approaches (such as informed consent) may not be feasible in some study designs. For example, cluster randomized trials pose inherent challenges to confidentiality. In these studies, where clusters (e.g., hospitals or communities) are randomized, accountability mechanisms may require disclosing to individuals if their data is compromised and the steps taken to address it. If participants were unaware they were part of a study, notifying them of a data breach could inadvertently reveal the research activity, potentially eroding trust among some participants [31]. Equipoise The ethical concept of equipoise in implementation research differs from its traditional application in clinical trials. In traditional clinical trials, equipoise refers to the uncertainty about a treatment’s efficacy. In contrast, in implementation trials, ethical approval depends on uncertainty about the implementation process rather than the intervention itself [4, 47]. Furthermore, Seward and colleagues introduce the concept of contextual equipoise to account for diverse factors such as community needs, resource availability, and stakeholder priorities, which are critical in determining what constitutes uncertainty or balance when rolling out different arms of an implementation research trial [17]. Equipoise in implementation research trials is further complicated by challenges such as the ethical implications of delaying interventions for control groups or testing delivery methods for established interventions [2]. These challenges raise concerns about justice, fairness, and risk–benefit evaluations for ethical review boards [2, 5, 28]. Researchers argue that assessments of equipoise in implementation research trials must carefully consider both the intervention’s effectiveness, typically already established, and its practical application across diverse social, cultural, and healthcare settings [17, 26, 51]. Equity Several authors highlight power imbalances, disparities in access to crucial interventions, and systemic inequities as important equity concerns in implementation research. Power dynamics between local communities, research institutions, and international donors can influence the identification of implementation priorities [41, 49]. These dynamics raise concerns about unfair priority setting that do not reflect the local health system needs and priorities, coercion [41], inadequate informed consent, and marginalized voices being excluded due to socio-economic or colonial legacies [42, 43]. Some authors focus on access disparities, particularly in the adoption and scale-up of technologies and treatments in under-resourced settings, which can exacerbate health inequities [35, 43], while Pratt and colleagues advocate for health systems research that responds to local needs, addresses structural factors such as human resources and health information systems, and promotes fairness in outcomes [49]. Additionally, community engagement is emphasized as essential for ensuring local empowerment and equitable distribution of benefits in the research process [39]. Informed consent Informed consent procedures present complex ethical challenges in implementation research, particularly in group-level interventions and cluster randomized trials. These challenges sometimes require dual consent from both cluster- or community-level leaders and individual participants [2, 47]. In vulnerable populations, such as older adults and children, informed consent has been described as an ongoing, supported process to accommodate cognitive and physical limitations [19, 42, 43]. Furthermore, concerns about therapeutic misconceptions, where research participants confuse research with therapeutic care, underscore the importance of clear communication to ensure participants fully understand the nature of their involvement [20]. Key themes include adopting a systematic approach to adapting consent processes to local cultural, linguistic, and power dynamics, particularly in LMICs, where authority figures and community leaders play significant roles in the consent process [28, 29]. To navigate these challenges, researchers must balance respect for autonomy with practical feasibility, often utilizing alternative consent mechanisms or community engagement to ensure transparency and ethical rigor [44, 51]. Minimal risk Authors highlight the difficulty of assessing risks in implementation research, where new delivery methods may present less immediate and harder-to-measure risks, complicating ethical review [27, 29]. Ethical dilemmas arising from the overlap between personal and professional roles among research team members, as well as inequities in distribution of effective, evidence-based interventions among clusters in a randomized controlled trial, were also discussed as unintended consequences [39, 40]. The ambiguity in distinguishing between research and non-research public health activities was especially relevant, with authors noting that even low-risk activities may require ethical review due to potential harm [26]. Some authors criticized research trials for inadequately addressing the social vulnerability of participants and advocated for a clearer justification of cluster-focused study designs based on theoretical foundations and principles such as distributive justice [27]. These gaps create challenges for researchers and research ethics committees in defining and managing minimal risk effectively. Kim and colleagues provide a systematic framework for assessing risk in pragmatic trials, emphasizing the need to evaluate standard care, participant burdens, and welfare outcomes [30]. Scientific validity Our review identified scientific validity as an important ethical issue in implementation research, particularly in selecting research designs that balance methodological rigor with contextual considerations. Several studies emphasized that research designs should be chosen based on their ability to address the specific research question and context, rather than defaulting to traditional methods such as individually randomized controlled trials [21, 38]. The review also highlighted discussions on non-traditional designs, such as cluster randomized and stepped-wedge trials, which should not be dismissed as "alternative" if they meet scientific and ethical standards. Findings further indicated that ethical integrity in study design requires equipoise and transparency regarding methodological limitations, particularly when interventions are delayed or withheld [5, 38]. In the context of big data, ethical reviews were noted as essential for addressing uncertainties and ‘black swan events’ – impactful events that cannot be predicted or prevented beforehand [15]. A few articles also noted that as health systems increasingly rely on advanced data-driven and automated analytic tools, some of which are AI driven, the uncertainties in implementation contexts may be further amplified [15, 34]. Additionally, challenges to scientific validity were reported in everyday settings, such as schools and hospitals, where participants are enrolled in multiple and overlapping trials, often conflating the true effects of individual trial findings, and may introduce confounding variables [1, 14]. The review also identified difficulties in maintaining scientific rigor in participatory action research within health systems research, particularly when interventions evolve in response to community needs, deviating from the original scientific hypothesis [22]. Risk to benefit ratio The ethical challenges of assessing the risk-to-benefit ratio in implementation research are multifaceted, particularly when conducting studies in low-resource settings. Key concerns include the difficulty in predicting harms, especially when risks extend beyond individual participants to affect communities and systems [13, 25]. New trial designs, such as stepped-wedge randomized trials, raise additional ethical dilemmas, particularly when participants may not directly benefit from the research [5, 21]. These include concerns about delayed access to potentially beneficial interventions, and the risk of exacerbating disparities among vulnerable populations due to staggered implementation. Informed consent is another critical issue, with some studies advocating for broad disclosure or simplified consent processes in cases where risks are perceived to be minimal [28, 31], while others stress the need for more detailed consent when risks are uncertain, even if perceived to be minimal [2, 38]. The complexity increases in resource-limited settings, where the benefits of research may be diffuse, and delays in intervention rollout are sometimes necessary due to limited evidence or resources [2, 20]. Ultimately, ethical guidelines must be developed and updated to navigate these challenges, ensuring that the benefits of research outweigh the risks, particularly for vulnerable and low-resource populations who may benefit from the interventions being implemented [33, 51]. Regulatory oversight The scoping review identified several challenges to ethical oversight in implementation research, including methodological complexities, regulatory ambiguities, and the inadequacy of traditional ethical frameworks. A key issue is the difficulty in distinguishing research from program evaluation or quality improvement, as this classification determines whether ethical review is required [2, 21, 25]. Ambiguities in this distinction often result in inconsistent oversight, particularly in complex designs such as stepped-wedge trials and cluster randomized trials [5, 38]. Traditional ethical guidelines, such as the Declaration of Helsinki, were critiqued for being biomedical-focused and poorly suited for health systems research, which involves system-level and non-linear interventions [13, 48]. The review also highlighted the need for capacity building within research ethics committees, to ensure they can effectively evaluate novel methodologies [5, 14]. To address these challenges, some authors advocated for flexible, integrated oversight mechanisms that engage both ethics experts and researchers to better accommodate the unique demands of implementation research [21, 51]. Additionally, findings emphasized the importance of context-sensitive oversight, particularly for government-led evaluations, to ensure ethical accountability while avoiding unnecessary barriers to valuable studies and interventions [18, 23]. Unintended consequences Burnout and increased workload Burnout and increased workload emerged as significant unintended consequences of conducting implementation research. Existing healthcare staff in overwhelmed systems often face additional strain from research tasks, necessitating the recruitment of extra staff to manage the dual responsibilities of clinical care and research [14]. Similarly, the rushed implementation of a palivizumab program in Nunavik led to excessive workloads for nurses and pharmacists, resulting in job dissatisfaction and burnout [19]. Ethical concerns were raised regarding demand-side interventions that strain already resource-constrained healthcare systems, with calls for researchers to address supply-side capacity to prevent overburdening staff [29, 33]. Other accounts emphasize structural inefficiencies and emotional labor. Increasing demands from surveys, audits, and policy pressures contributed to staff exhaustion and reduced morale [40, 52]. Emotional fatigue also emerged as a theme, with peer caregivers experiencing burnout from the dual demands of caregiving and sharing personal experiences [45]. Poorly executed training programs for therapists were shown to lead to dissatisfaction and high turnover [35], while excessive documentation burdens associated with electronic health records contributed to physician burnout [34]. Denial of standard of care The challenge of balancing research integrity with the obligation to provide equitable care is a concern in implementation research. Key ethical principles, such as beneficence and clinical equipoise, highlight the need to ensure that participants, particularly those in control groups, receive at least usual care or effective interventions [38]. The justification of delayed access to an intervention is contested, with arguments that it is insufficient reason for withholding care [38]. The importance of adapting research to local needs is also emphasized to avoid exposing vulnerable populations to harm [17]. A central challenge lies in defining standard care, with distinctions between "Local De Facto Standard" (care typically available in the region) and "Local De Jure Standard" (care endorsed by experts), both of which introduce ethical complexities when local care is inadequate or unsustainable [47]. Recommendations from the Ottawa Statement suggest that when a control group receives usual care [38], researchers must ensure that participants are not deprived of effective treatment, reinforcing the need to uphold ethical standards [26]. The selective nature of translational research further raises concerns about disparities in access to research benefits. Specific medical criteria for research participation often exclude broader community members who could benefit from the study findings, exacerbating existing inequities [20]. The de-implementation of low-value care also presents unintended consequences, as inadequate planning can worsen disparities in access to treatment, as seen in cases like contralateral prophylactic mastectomy [32]. Additionally, ethical dilemmas arise when testing new delivery methods, particularly when control groups are denied the same standard of care, creating tensions between fairness and maintaining research integrity [28]. Equity concerns Implementation research often encounters unintended equity concerns, particularly in resource-limited settings, where disparities in resources hinder the adoption of evidence-based practices [35]. Introducing new interventions without adequate resources can strain existing systems, as observed in Nunavik's immunoprophylaxis program, where resource diversion led to neglect of other critical healthcare services [19]. These challenges underscore the risk of widening disparities in access, quality, and outcomes across socio-economic, racial, and identity groups, as well as amplifying stigma in areas like mental health [35, 43]. Additionally, phased rollouts, such as stepped-wedge designs, delay access for some participants, raising ethical concerns about interim inequities [29, 47]. Ethical principles like justice, beneficence, and respect for dignity, while aspirational, often lack actionable guidance for addressing equity challenges in implementation research [40]. Inclusive post-approval research, which involves broader participant groups, is better positioned to reduce disparities compared to pre-approval studies with restrictive eligibility criteria [20]. Alternative research designs, such as pragmatic or hybrid approaches, can mitigate these issues but may trade off scientific rigor due to compromised randomization as well as reduced internal and external validity [47]. Addressing these equity concerns requires stakeholder engagement and policy interventions, such as subsidies or insurance coverage, to ensure equitable access and mitigate the risks of deepening disparities [43, 47]. Lack of sustainability Sustainability challenges, which arise when interventions are not designed for long-term success, are highlighted across several articles. Key issues include financial sustainability, as many interventions rely on external funding from governments or families, creating dependencies that may not be sustainable once the research phase ends [28, 43]. Ethical concerns also arise, particularly with monetary incentives, as these can lead to participation driven by financial gain, affecting study outcomes and participant retention [37]. Additionally, the dynamic nature of healthcare systems, including evolving policies, staff turnover, and changing demographics, complicates the ability to maintain program fidelity and long-term relevance [11, 39]. Structural barriers, especially in low- and middle-income countries, such as fragmented governance and slow policy translation, further hinder the scalability and sustainability of successful interventions [22, 29]. To address these challenges, proactive planning, stakeholder responsibility, and community engagement are crucial to ensuring that interventions remain effective and accessible in the long term [29, 47]. Loss of autonomy Various methods in implementation research, such as performance measurement, pragmatic trials, incentives, and technology, can unintentionally compromise patient and participant autonomy. In healthcare settings, performance measurement systems and research designs like cluster randomized trials can shift focus from individualized patient care to meeting performance targets or adhering to research protocols, potentially undermining patients' ability to make informed, autonomous decisions [29, 35, 36, 47]. The use of incentives in health research is also debated, with some arguing that they can coerce participants into decisions they wouldn’t normally make, while others suggest that well-designed incentives can empower individuals and enhance autonomy by overcoming barriers to care [28, 29, 33]. Furthermore, technology, especially in managing health for older adults, may diminish personal control, raising concerns about the loss of autonomy [43]. There continues to be an emphasis on transparent decision-making, using ethical frameworks adapted for implementation research, and thoughtful research designs to mitigate these unintended consequences and ensure that both individual and collective autonomy are respected in health research contexts [39, 47]. Stigma Several authors highlight that while interventions such as screenings or health technologies may offer significant benefits, they can also inadvertently stigmatize vulnerable populations, such as individuals with mental health conditions, men who have sex with men, or women in LMICs [27, 28, 35, 37]. Ethical concerns are raised regarding the balance between potential benefits and stigma risks, with suggestions for safeguarding strategies in research design, such as situational analysis and protecting confidentiality [41, 47]. Furthermore, the impact of cultural and social contexts is emphasized, with interventions that work in one setting potentially causing harm in another if stigma risks are not adequately addressed [27, 47]. Authors call for a thoughtful, culturally sensitive approach to implementation research to mitigate stigma while maximizing the positive impact of health interventions [17, 43]. Loss of trust The scoping review identified loss of trust as a significant unintended consequence in implementation research, particularly in culturally distinct or sensitive contexts. Mistrust can arise when financial incentives are poorly understood or culturally misaligned, as observed in a study on mental health and HIV in Malawi, where participants associated these incentives with sinister motives, hindering recruitment and retention [14]. Similarly, concerns over confidentiality during data collection, such as the use of audio recordings, were found to cause participant hesitation and undermine trust in the research process [40]. The review also highlighted the impact of sustainability planning on community trust. A lack of post-research follow-up can erode confidence, particularly when participants feel abandoned after the study concludes [47]. Financial conflicts of interest were identified as another factor that can damage public trust, especially when information is withheld for financial gain, compromising the integrity of the research [20]. Additionally, cultural insensitivity and poor communication were found to exacerbate misunderstandings and deepen mistrust in the implementation of healthcare programs [19]. Ethical challenges related to transparency and confidentiality were particularly pronounced in low-income settings, where balancing participant rights with the dissemination of research findings is crucial to maintaining trust [41]. Existing ethical guidance relevant to the responsible conduct of implementation research Table 4 summarizes the ethical frameworks and guidelines identified in the scoping review, highlighting the ethical principles they cover and their applicability across various research designs and settings. Several frameworks [30, 31, 38, 51, 57] address the ethical challenges, such as difficulties in obtaining informed consent, challenges in risk assessment, less control over variables, and issues with participant recruitment, associated with pragmatic clinical trials, cluster randomized trials, and other implementation trials, where groups rather than individuals are randomized and research is conducted in complex, real-world settings. Table 4Existing ethical guidance relevant to the responsible conduct of implementation researchGuidanceDescriptionWorld Health Organization’s Ethical Considerations for Health Policy and Systems Research [54]Provides key considerations for research teams to identify and address ethical issues in health policy and systems research, such as respect, harm reduction, justice, power dynamics, and accountability, across diverse contexts. The updated guidance includes a section on implementation science, recognizing that clinical equipoise may justify evaluating proven interventions in new settings where evidence is limitedRattani and Hyder’s Proposed Checklist for Ethical Review [33]A 10-item checklist covering research subjects, informed consent, community engagement, benefits, risks, dissemination, and sustainability, aimed at strengthening ethical standards in global health researchThe Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials [38]Provides 15 recommendations to ensure ethical rigor in cluster trials, addressing challenges like informed consent, gatekeeper roles, participant identification, and the protection of vulnerable participantsThe International Ethical Guidelines for Health-related Research Involving Humans [55]Provides guidance on ethical national policies, local application of standards, and ethical review mechanisms, especially in LMICs. The 2016 update addresses implementation research in cluster randomized trialsWHO Ethics in Implementation Research Facilitator’s Guide [56]This is a 6-module training course guide for researchers and ethics committees on key ethical considerations in implementation research. It includes didactic materials with case studies, role-playing, and quizzes that address ethical dilemmas related to the planning, conduct, and post-conduct phases of implementation researchQuintet Recruitment Intervention (QRI) [57]A framework to optimize participant recruitment in randomized controlled trials, including pragmatic trials by identifying barriers to recruitment, improving communication with potential participants, and ensuring diverse enrollmentKrubiner & Hyder's Bioethical Framework for Health Systems [58]The framework draws on governance, human rights, and business ethics to outline 11 ethical principles that guide the development of just and effective health systems. It addresses key challenges in LMICs, including ensuring equitable access, managing limited resources, and fairly distributing health benefits and burdensKim & Kimmelman’s Framework for Identifying Research Risk in Pragmatic Trials [30]Provides a four-step process to assess risks in pragmatic trials, ensuring that pragmatic trials are ethically sound, while balancing the need for real-world evidence with the protection of participants and providing clear guidance on how to approach risk assessment in such complex research contextsEmanuel Framework [59]Outlines eight ethical principles for clinical research, adapted to address the unique challenges of implementation research in low-resource settings: partnership, social value, validity, fair selection, benefit-risk balance, independent review, consent, and respectWolfenden’s Best Practice Guidance for the Development and Conduct of Randomized Implementation Trials [51]Provides comprehensive guidance on essential aspects of implementation trial design and conduct, including defining trial objectives, developing recruitment and retention strategies, selecting appropriate randomized designs, integrating theoretical frameworks, identifying relevant measures, calculating sample sizes, addressing ethical considerations, and improving reporting standardsMorain’s Eight Dimensions of Respect for Persons in the Ethical Design, Conduct, and Oversight of Pragmatic Clinical Trials [31]Proposes eight dimensions of respect for pragmatic trials, extending beyond traditional consent to include community engagement, transparency, agency, burden minimization, privacy protection, positive interactions, compensation, and social value Existing ethical guidance relevant to the responsible conduct of implementation research More broadly, ethical frameworks such as the WHO Ethical Considerations for Health Policy and Systems Research [54], Rattani & Hyder’s Proposed Checklist for Ethical Review [33], and Krubiner & Hyder’s Bioethical Framework for Health Systems [58] reflect the complexities of health policy and systems research, including global health systems. These frameworks provide valuable guidance on managing ethical risks, balancing equity with efficiency, and ensuring fairness in risk–benefit distributions, all of which are ethical considerations pertinent to implementation research. The International Ethical Guidelines for Health-related Research Involving Humans [55], and the Emanuel Framework [59] were originally developed for clinical and biomedical research but have been adapted to incorporate some ethical considerations specific to implementation research [13]. These adaptations address concerns such as conducting research in low-resource settings and equity issues in withholding effective treatment from control groups in cluster randomized trials. One framework specifically tailored to implementation research is the WHO Ethics in Implementation Research Facilitator’s Guide [56]. Unlike other frameworks, this is an ethical training course designed to guide both researchers and ethics committees in navigating ethical dilemmas unique to implementation research. Some of these dilemmas involve power imbalances, stakeholder interests, and the potential for unintended consequences, highlighting the need to balance scientific rigor with the complexities of local contexts, ensure informed consent, protect vulnerable populations, foster community engagement, and promote transparency and accountability in research processes. Discussion This scoping review explored ethical principles and questions that arise in the conduct of implementation research, along with associated risks and unintended consequences. Additionally, we examined ethical frameworks or guidelines used in implementation research. Three key findings emerged. First, we found that the ethical principles identified were generally related to the responsible conduct of research and were not specific to implementation research, which inherently includes multilevel strategies and assessments. As such, the application of these principles presents challenges such as difficulties in obtaining informed consent, balancing risks and benefits across multiple stakeholders, and ensuring equity when implementing interventions in diverse, resource-limited settings, as well as in adaptive study designs. Second, the risks and unintended consequences associated with implementation trials were distinct. Studies were not primarily concerned with the risk of clinical adverse events but instead focused on risks inherent to the socio-behavioral aspects and other unforeseen burdens of research conduct. Third, while guidance on the responsible conduct of implementation research is insufficient, emerging frameworks highlight pertinent ethical issues, such as participant recruitment, informed consent, and cluster randomized trial designs. However, consensus standards remain lacking among both implementation researchers and ethical review boards. Our findings highlight informed consent, equipoise, regulatory oversight, and risk–benefit ratio as common ethical domains requiring attention. These domains are interrelated and often center on how implementation research studies are evaluated by regulatory bodies, which, in turn, influence decisions regarding the level of participant consent and other traditional ethical requirements. The growing use of adaptive trail designs, where randomization, sample allocation, or intervention components are modified based on interim analyses, further complicates these evaluations [60]. Such study designs in implementation research depend more heavily on contextual equipoise where uncertainty pertains not to an intervention’s efficacy (as in clinical equipoise) but to its feasibility, acceptability, and appropriateness in a given setting [17]. Even the 2017 Hastings Center Report, which argues that clinical equipoise is the most critical ethical standard for reviewing adaptive trial designs, acknowledges that the ethical value of adaptive designs is highly situation-dependent and as such, requires that researchers and review boards have “methodological expertise in adaptive statistics, robust data-monitoring procedures, and familiarity with context-dependent risks” to avoid making blanket claims [60]. However, many research ethics committees, particularly in low- and middle-income countries, operate with limited staffing, infrequent meetings, high protocol backlogs, and insufficient training in adaptive study designs employed in implementation research [61]. These constraints limit their capacity to critically evaluate methodological assumptions, monitor accumulating data, or weigh context-specific equipoise claims. Regarding risk–benefit ratios, its assessment in implementation trials is often not commensurate with the actual risks involved, as these risks remain unclear to both researchers and ethical review boards [33, 38]. Others have reported that, due to the paucity of evidence on the specific risks posed by implementation research, and the extent to which these risks are truly minimal, ethical review boards often struggle to adequately assess such studies [30, 31]. As a result, they may impose excessive oversight requirements or engage in prolonged back-and-forth deliberations with researchers to determine the appropriate level of oversight. Our findings on the risks and unintended consequences in implementation research underscore the need for ethical risk assessment in implementation research to extend beyond individual participants and account for systemic risks and benefits across multiple levels, including patients, healthcare providers, and institutions. This includes considering unintended consequences such as loss of trust, burnout, stigma, equity concerns, lack of sustainability, and the denial of standard care. These risks, which are often psychosocial rather than related to clinical adverse events, are noteworthy. Other authors have referred to these as "ripple effects" [35], “black swan effects” [15], "paradoxical effects" [62] and evidence is gradually accumulating on their impact, which may be more common and inherent to implementation trials. Patient-level adverse events in implementation trials are also beginning to be conceptualized [63]. Goss and colleagues propose a conceptual model that identifies four types of adverse events in implementation trials, clarifying the mechanisms linking implementation strategies to patterns of intervention use and potential patient-level harms [63]. Explicitly integrating these unintended consequences and potential adverse events into ethical discussions is crucial, as failing to do so may undermine both the ethical and practical viability of implementation strategies. This may also help in defining what constitutes “minimal risk” for implementation research studies, a key consideration for ethical review boards. A thorough understanding of what risks are considered minimal in implementation trials is essential for determining appropriate oversight levels. Numerous ethical frameworks have been developed to guide responsible research conduct in health systems research broadly, many of which have either been designed for study methods relevant to implementation research [30, 31, 38, 51, 57] or adapted for it [13, 55, 56]. However, these frameworks remain fragmented, addressing only specific aspects of implementation research ethics. The most common focus areas are participant recruitment [54, 57, 58], autonomy, and respect in low-resource international settings [54, 55], as well as ethical considerations in cluster randomized and pragmatic trial designs [31, 38]. Moreover, these frameworks are often designed to guide researchers rather than research ethics committees, and they do not provide clear guidance on defining or assigning minimal risk. Adapting existing frameworks to incorporate risk assessment based on what is considered minimal presents an opportunity to better guide research teams and ethical review boards in making oversight decisions that align with study design and risk levels. Beyond adapting frameworks to the unique ethical considerations of implementation research studies, our findings point to several practical strategies that health systems, research teams, and community partners can employ in operationalizing ethical principles in real-world implementation science settings. First, both research teams and ethical review boards would benefit from capacity building efforts, including trainings on ethical considerations, unique risks, benefits, and unintended consequences, needed to effectively adjudicate implementation research studies. Second, embedding early and ongoing consultation between research teams, implementation partners, and Institutional Review Boards using models such as pre-review meetings or staged protocol review can reduce misalignment around risk–benefit assessments and consent procedures. Third, partnering with end-users (patients and participants) throughout the research process can help ensure that ethical frameworks are applied in contextually appropriate ways particularly in settings where individual informed consent is impractical. Also, engaging with community members helps secure buy-in and commitment needed for the scale-up and sustainability of an effective intervention and is critical in priority setting that reflects local context. Finally, funding agencies have an important role in further advancing the field by investing in empirical investigations into the risks and unintended consequences of implementation research. This is echoed in recent scholarship which reports that the mapping of implementation strategies to their unintended consequences is a foundational step toward developing consensus-based ethical standards for implementation research [4]. These are relevant directions the field must pursue to advance ethical implementation research. Although implementation research is still a relatively emerging field, it has already recorded notable successes by accelerating the translation of proven interventions into practice, strengthening health systems, improving equity, and increasing the return on investment of health innovations, particularly in low-resource settings where delays in implementation can translate into preventable morbidity and mortality. For example, the Global Pediatric Acute Critical Illness Study in multi-centers in LMICs demonstrates how implementation-focused trials can advance global health equity by standardizing infection-prevention practices, building local research infrastructure, and strengthening institutional ethics capacity [61]. Similarly, adaptive implementation trials, when ethically sound, can accelerate the translation of beneficial interventions into practice by reducing participant exposure to ineffective strategies and improving trial efficiency, as shown by the influence of early neonatal extracorporeal membrane oxygenation trials on widespread changes in critical care practice [60]. Given these societal benefits, our recommendation for investments in developing ethical standards that identify and accommodate ethical considerations relevant to implementation research are, not merely procedural improvements but, central to fully realizing the public health benefits of implementation research. This review has important limitations. First, we may have missed some publications due to publication bias or restrictions in our search strategy. Also, our review focused primarily on broad ethical principles and emerging frameworks, which may not fully capture context-specific ethical challenges in different implementation research settings or for specific implementation strategies. Although 22% of the included studies focused on LMICs, nearly half were commentaries and most (80%) first authors were from the Americas or Europe, which may bias the findings and underrepresent ethical challenges faced by researchers in low-resource or historically underrepresented settings. Lastly, our findings primarily reflected negative unintended consequences, yet we acknowledge that implementation strategies may also generate unanticipated positive effects, for example, by revealing additional needs or priorities within a setting. In our analysis, the focus on negative unintended consequences reflects both the experiences participants described and the relevance of these consequences to ethical review, including considerations of burden, workflow disruption, and whether an implementation activity may exceed minimal risk. At the same time, we recognize that unintended consequences, whether positive or negative, are unlikely to be evenly distributed across individuals or settings, and anticipating this variability remains challenging. We see this as an important area for future research. Conclusions This scoping review identified key ethical domains, unintended consequences and gaps in ethical guidance, emphasizing the need for a cohesive ethical framework tailored to implementation research. Future research should build on these findings by conducting empirical studies that deepen our understanding and support the development of a consensus-driven ethical framework. Furthermore, refining ethical standards should be done alongside training for researchers and ethics committees for improved oversight and support in the responsible conduct of implementation research. Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Supplementary Material 5. Acknowledgements The authors would like to acknowledge the Heart, Lung, and Blood Co-morbiditieS Implementation Models in People Living with HIV (HLB SIMPLe) Alliance for their support on this work. Abbreviations The Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews Joanna Briggs Institute Pragmatic Clinical Trials Cluster Randomized Trials Health Policy and Systems Research Low- and Middle-Income Countries Research Ethics Committee Authors’ contributions EKT, ALA, BJP, and MDH conceived the subject matter for this review, and secured funding for this work. MD developed the scoping review protocol and conducted the search strategy. EKT, NA, and GAM conducted the abstract screening, full-text screening, and the data extraction. EKT performed the data analysis and drafted the first version of the article. All authors (EKT, NA, GAM, MD, EHG, BJP, MDH and ALA) edited, read, and approved the submitted manuscript. Funding This project is supported by the Washington University, Institute for Public Health, Center for Dissemination and Implementation Conceptual and Methodological Review (CAM) Grant Program. The content is solely the responsibility of the authors and does not necessarily represent the official view of Washington University. Data availability Not Applicable. Declarations Ethics approval and consent to participate This study received approval from the Washington University in St. Louis Institutional Review Board (IRB ID#-202403208). Consent for publication Not Applicable. Competing interests Dr. Huffman has patents pending related to heart failure polypills. George Health Enterprises Pty Ltd (GH) and its subsidiary, George Medicines Pty Ltd, have received investment funds to develop fixed-dose combination products, including combinations of blood pressure-lowering drugs. GH is the social enterprise arm of The George Institute for Global Health. Elvin Geng is the Editor-in-Chief of Implementation Science Communications. All other authors have no disclosures or financial conflicts of interest. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Supplementary Material 5. Data Availability Statement Not Applicable.